These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
|Articles|June 12, 2021
Challenges with New Care Delivery Systems in Cardiology
Author(s)Gregory M. Weiss, MD
The final slideshow in our multipart series, this slideshow examines the scope of work and conclusions from the AHA/ACC task force who tackled the topics of overcoming hurdles with new care delivery systems for the American Heart Association/American College of Cardiology Consensus Conference on Professionalism and Ethics.
Advertisement
The last slideshow in our multipart series, this slideshow examines the scope of work and conclusions from the AHA/ACC task force who tackled the topics of overcoming hurdles with new care delivery systems in cardiology in cardiology for the American Heart Association/American College of Cardiology Consensus Conference on Professionalism and Ethics.
This report, "
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Advertisement
Advertisement